NCT05447013 (CoV-2-STs) is a Phase 1, PHASE2 clinical trial of Coronavirus-2-specific T cells in Severe COVID-19, sponsored by George Papanicolaou Hospital.

Who is sponsoring NCT05447013?

NCT05447013 is sponsored by George Papanicolaou Hospital.

What drugs are being tested in NCT05447013?

Interventions in NCT05447013: Coronavirus-2-specific T cells, standard of care (SOC).

What condition does NCT05447013 study?

NCT05447013 studies Severe COVID-19.

Is NCT05447013 still recruiting?

NCT05447013 is currently status unknown. Last updated 23 November 2022.

Last reviewed 2022-11-23 · How we verify

NCT05447013: CoV-2-STs

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients

Status unknown Phase 1, PHASE2 Last updated 23 November 2022

What this trial tests

Phase 1, PHASE2 trial testing Coronavirus-2-specific T cells in Severe COVID-19 in 182 participants. Status unknown.

Timeline

2 June 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	George Papanicolaou Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	182
Start date	2 June 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	2 locations across Greece

Drugs / interventions tested

Coronavirus-2-specific T cells — full drug profile →
standard of care (SOC) — full drug profile →

Conditions studied

Severe COVID-19 — all drugs for Severe COVID-19 →

Sponsor

George Papanicolaou Hospital

Who can join

Adults 18 to 80, any sex, with Severe COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-label phase I (single-center)/ phase II (multicenter) with randomization 2:1

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
Arevalo-Romero JA, Chingaté-López SM, Camacho BA, Alméciga-Díaz CJ, et al · · 2024 · cited 13× · PMID 38434363 · DOI 10.1016/j.heliyon.2024.e26423
Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.
Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, et al · · 2023 · cited 11× · PMID 36698615 · DOI 10.1097/hs9.0000000000000809
Immune-Cell-Based Therapy for COVID-19: Current Status.
Wang Y, Liang Q, Chen F, Zheng J, et al · · 2023 · cited 3× · PMID 38005826 · DOI 10.3390/v15112148
Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities.
Nova Z, Zemanek T, Botek N. · · 2022 · cited 1× · PMID 36499448 · DOI 10.3390/ijms232315122
Early Immunological Biomarkers for Personalized Treatment Selection in Severe COVID-19: Post Hoc Machine Learning Analysis of a Randomized Clinical Trial.
Savvopoulos S, Papadopoulou A, Karavalakis G, Sakellari I, et al · · 2026 · PMID 42241692 · DOI 10.2196/78471

Verify or expand the search:

Other recruiting trials for Severe COVID-19

Currently open trials in the same condition.

NCT05233605 — Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation · recruiting

Other George Papanicolaou Hospital trials

Trials by the same sponsor.

NCT05471661 — T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Tr · Phase 1, PHASE2 · completed
NCT07024914 — Effect of Oxygen Supplementation on Cerebral Oxygenation, Symptoms and Performance During STST in COPD Patients · NA · active not recruiting
NCT03683082 — Oxygen Treatment and Pulmonary Arterial Hypertension · NA · unknown
NCT03688334 — Acute Effects of Oxygen Supplementation Among IPF Patients · NA · unknown
NCT03248076 — Effect of Fentanyl on Main Opioid Receptor (OPRM1) on Human Granulosa Cells. · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05447013 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by George Papanicolaou Hospital
Last refreshed: 23 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05447013.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing